{"id":"W2994917610","doi":"10.1200/jco.19.01455","title":"NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":420,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"National Cancer Institute; American Society of Clinical Oncology; Amgen; Pfizer; Eli Lilly and Company; Genentech","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Hazard ratio; Cyclophosphamide; Docetaxel; Chemotherapy; Immunohistochemistry; Adjuvant; Cancer; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001894626,0.001399752,0.002115537,0.0004554611,0.0003371761,0.00075574,0.0007198509,0.001251845,0.004480266],"category_scores_gemma":[0.001522979,0.0005431481,0.001367611,0.0004180789,0.001194578,0.0006450173,0.0003738207,0.002419976,0.0006681312],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001036783,"about_ca_system_score_gemma":0.00159501,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001911071,"about_ca_topic_score_gemma":0.004261418,"domain_scores_codex":[0.9991725,0.0005549965,0.00003383696,0.00009166595,0.00005168424,0.00009532714],"domain_scores_gemma":[0.9991811,0.0001995419,0.0001927181,0.00005999286,0.00004192065,0.0003246795],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9848493,0.003458472,0.0007574642,0.0001679061,0.0004046018,0.00002096909,0.00002428025,0.0003438707,0.001535653,0.0001089451,0.0005663671,0.007762131],"study_design_scores_gemma":[0.9445882,0.05200861,0.001666587,0.00002109678,0.0003297252,0.00002384469,0.00001177551,0.0003760117,0.0002975606,0.0001664994,0.0005027129,0.000007395058],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870744,0.003079864,0.0005204659,0.0008486853,0.0004446816,0.004349429,0.001134002,0.00008327032,0.002465311],"genre_scores_gemma":[0.9860771,0.002099636,0.001283655,0.001282589,0.0003870505,0.004271238,0.001348937,0.00001991139,0.003229735],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004480266,"threshold_uncertainty_score":0.01498801,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1163470475283686,"score_gpt":0.5119909698977256,"score_spread":0.3956439223693571,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}